Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression

Brain

Volumn 138, Issue 4, 2015, Pages 1023-1035

  Huijbers, Willem ^a   Mormino, Elizabeth C ^a   Schultz, Aaron P ^a   Wigman, Sarah ^a   Ward, Andrew M ^a,b   Larvie, Mykol ^a   Amariglio, Rebecca E ^a   Marshall, Gad A ^a   Rentz, Dorene M ^a   Johnson, Keith A ^a   Sperling, Reisa A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

amyloid deposition; clinical progression; functional MRI; hippocampal activation; MCI

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; DEMENTIA; DISEASE COURSE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; ATROPHY; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES;

AGED; AMYLOID BETA-PEPTIDES; ATROPHY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT;

EID: 84929118642     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv007     Document Type: Article

References (88)

1. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al. Clinical core of the Alzheimer's disease neuroi-maging initiative: progress and plans. Alzheimers Dement 2010; 6: 239-46.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
3. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012; 74: 467-74.
4. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-b deposition. Nat Pub Group 2011; 14: 750-6.
5. Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 2005; 64: 501-8.
6. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343: 450-6.
7. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
8. Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, et al. Increased fMRI signal with age in familial Alzheimer's disease mutation carriers. NBA 2012; 33: 424e11-21.
9. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004; 23: 724-38.
10. Cabeza R. Hemispheric asymmetry reduction in older adults: the HAROLD model. Psychol Aging 2002; 17: 85-100.
11. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and alzheimer's disease: an independent component analysis. J Neurosci 2006; 26: 10222-31.
12. Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, et al. Accelerated cortical atrophy in cognitively normal elderly with high-amyloid deposition. Neurology 2012; 78: 477-84.
13. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-b levels in vivo. Neuron 2005; 48: 913-22.
14. Dale AM. Optimal experimental design for event-related fMRI. Hum Brain Mapp 1999; 8: 109-14.
15. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999; 9: 179-94.
16. Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh-Bohmer KA, et al. Temporal lobe functional activity and connectivity in young adult. Alzheimers Dement 2010; 6: 303-11.
17. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56: 27-35.
18. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
19. Elman JA, Oh H, Madison CM, Baker SL, Vogel JW, Marks SM, et al. Neural compensation in older people with brain amyloid-b deposition. Nat Neurosci 2014; 17: 1316-8.
20. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011; 34: 430-42.
21. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, et al. Distinct patterns of brain activity in young carriers of the APOE-"4 allele. Proc Natl Acad Sci USA 2009; 106: 7209-14.
22. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
23. Fox J, Weisberg S. An R companion to applied regression. 2nd edn., University of Minnesota, Sage Publications; 2011.
24. Hanseeuw B, Dricot L, Kavec M, Grandin C, Seron X, Ivanoiu A. Associative encoding deficits in amnestic mild cognitive impairment: a volumetric and functional MRI study. Neuroimage 2011; 56: 1743-8.
25. Hatashita S, Yamasaki H. Diagnosed mild cognitive impairment due to alzheimer's disease with pet biomarkers of beta amyloid and neuronal dysfunction. PLoS One 2013; 8: e66877.
26. Hämäläinen A, Pihlajamaki M, Tanila H, Hänninen T, Niskanen E, Tervo S, et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging 2007; 28: 1889-903.
27. Hinrichs C, Singh V, Xu G, Johnson SC, Initiative TADN. Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage 2011; 55: 574-89.
28. Huijbers W, Mormino EC, Wigman SE, Ward AM, Vannini P, McLaren DG, et al. Amyloid deposition is linked to aberrant entorh-inal activity among cognitively normal older adults. J Neurosci 2014; 34: 5200-10.
29. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-80.
30. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-65.
31. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010; 133: 3336-48.
32. Jack CR, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013; 81: 1732-40.
33. Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 2013; 77: 219-34.
34. Jagust WJ, Mormino EC. Lifespan brain activity. Trends Cogn Sci 2011; 15: 520-6.
35. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-34.
36. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013; 9: S72-83.
37. Johnson SC, Baxter LC, Susskind-Wilder L, Connor DJ, Sabbagh MN, Caselli RJ. Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia 2004; 42: 980-9.
38. Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging 2006; 27: 1604-12.
39. Johnson SC. The influence of alzheimer disease family history and apolipoprotein e 4 on mesial temporal lobe activation. J Neurosci 2006; 26: 6069-76.
40. Kennedy KM, Rodrigue KM, Devous MD Sr, Hebrank AC, Bischof GN, Park DC. Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage 2012; 62: 1-8.
41. Kircher TT, Weis S, Freymann K, Erb M, Jessen F, Grodd W, et al. Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J Neurol Neurosurg Psychiatr 2007; 78: 812-8.
42. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230-8.
43. Lenzi D, Serra L, Perri R, Pantano P, Lenzi GL, Paulesu E, et al. Single domain amnestic MCI: a multiple cognitive domains fMRI investigation. NBA 2011; 32: 1542-57.
44. Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 2003; 61: 500-6.
45. Marshall GA, Donovan NJ, Lorius N, Gidicsin CM, Maye J, Pepin LC, et al. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci 2013; 25: 302-7.
46. Mathalon DH, Sullivan EV, Rawles JM, Pfefferbaum A. Correction for head size in brain-imaging measurements. Psychiatry Res 1993; 50: 121-39.
47. Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE "4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014; 82: 1760-7.
48. Mormino EC, Brandel MG, Madison CM, Marks S, Baker SL, Jagust WJ. A deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex 2012; 22: 1813-23.
49. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated-amyloid deposition in elderly subjects. Brain 2009; 132: 1310-23.
50. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic. Alzheimer Dis Arch Neurol 2009; 66: 1469-75.
51. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status. J Neuropathol Exp Neurol 2012; 71: 362-81.
52. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibril-lar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012; 40: 104-14.
53. O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN, Blacker D, Dickerson BC, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010; 74: 1969-1976.
54. Oh H, Jagust WJ. Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid. J Neurosci 2013; 33: 18425-37.
55. Ossenkoppele R, Prins ND, van Berckel BN. Amyloid imaging in clinical trials. Alzheimers Res Ther 2013; 5: 36.
56. Ossenkoppele R, van der Flier WM, Verfaillie SCJ, Vrenken H, Versteeg A, van Schijndel RA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology 2014; 82: 1768-75.
57. Palop JJ, Mucke L. Amyloid-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010; 13: 812-8.
58. Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocog-nitive scaffolding. Annu Rev Psychol 2009; 60: 173-96.
59. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013; 74: 199-208.
60. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men the mayo clinic study of aging. Neurology 2010; 75: 889-97.
61. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-94.
62. Petrella JR, Krishnan S, Slavin MJ, Tran T-TT, Murty L, Doraiswamy PM. Mild cognitive impairment: evaluation with 4-T functional MR imaging 1. Radiology 2006; 240: 177-86.
63. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-47.
64. Putcha D, Brickhouse M, O'Keefe K, Sullivan C, Rentz D, Marshall G, et al. Hippocampal hyperactivation associated with cortical thinning in alzheimer's disease signature regions in non-demented elderly adults. J Neurosci 2011a; 31: 17680-8.
65. Putcha D, O'Keefe K, LaViolette P, O'Brien J, Greve D, Rentz DM, et al. Reliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults. Hum Brain Mapp 2011b; 32: 2027-44.
66. Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrillón G, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol 2010; 68: 865-75.
67. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-56.
68. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012; 61: 1402-18.
69. Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784-91.
70. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486-8.
71. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012; 109: E2895-903.
72. Selkoe DJ. Preventing Alzheimer's disease. Science 2012; 337: 1488-92.
73. Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 1999; 45: 466-72.
74. Sperling R. The potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol Aging 2011; 32: S37-43.
75. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
76. Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatr 2003; 74: 44-50.
77. Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, et al. Functional alterations in memory networks in early alzheimer's disease. Neuromol Med 2010; 12: 27-43.
78. Sperling RA, LaViolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63: 178-88.
79. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Trans Med 2014; 6: 228fs13.
80. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012; 11: 1006-12.
81. Trivedi MA, Murphy CM, Goetz C, Shah RC, Gabrieli JDE, Whitfield-Gabrieli S, et al. fMRI activation changes during successful episodic memory encoding and recognition in amnestic mild cognitive impairment relative to cognitively healthy older adults. Dement Geriatr Cogn Disord 2008a; 26: 123-37.
82. Trivedi MA, Schmitz TW, Ries ML, Hess TM, Fitzgerald ME, Atwood CS, et al. fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer's disease. Neuropsychologia 2008b; 46: 1667-78.
83. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.
84. Visser PJ, Verhey FRJ, Hofman PAM, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatr 2002; 72: 491-7.
85. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TLS, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011; 70: 857-61.
86. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-68.
87. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37-49.
88. Zeileis A, Grothendieck G. zoo: S3 infrastructure for regular and irregular time series. J Stat Softw 2005; 14: 1-27.